ADMA Court News: ADMA Biologics Class Action Lawsuit Alleges Securities Fraud on behalf of Investors with Losses

A securities fraud class action lawsuit has been filed on behalf of ADMA Biologics investors after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws. Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA ) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. Investors have until August 10, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in ADMA securities. The class action is pending in the U.S. District Court for the District of New Jersey. It is captioned Mazzarino v. ADMA Biologics, Inc., et al. , No. 26-cv-6918. ADMA has been sued for securities fraud following significant stock drops resulting from potential violations of the federal securities laws. The decline in AMDA's stock price caused significant losses to investors. ADMA is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing and developing specialty biologics. ADMA's flagship product is ASCENIV, a liquid immun...